Phase Ib, Open-label, Multi-center Study to Characterize the Safety, Tolerability and Pharmacodynamics (PD) of PDR001 in Combination With LCL161, Everolimus (RAD001) or Panobinostat (LBH589)

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 29 Mar 2022

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Everolimus (Primary) ; LCL 161 (Primary) ; Panobinostat (Primary) ; QBM 076 (Primary) ; Siremadlin (Primary) ; Spartalizumab (Primary)
Indications Adenocarcinoma; Advanced breast cancer; Colorectal cancer; Non-small cell lung cancer; Renal cell carcinoma; Triple negative breast cancer
Focus Adverse reactions
Sponsors Novartis Pharmaceuticals

11 Mar 2022 Status changed from active, no longer recruiting to completed.
19 Jan 2022 Planned End Date changed from 3 Feb 2022 to 23 Feb 2022.
19 Jan 2022 Planned primary completion date changed from 15 Dec 2021 to 23 Feb 2022.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com